Journal
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Volume 25, Issue 5, Pages 790-800Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s10147-019-01588-7
Keywords
Immune checkpoint inhibitor; Biomarker; Immune-related adverse event; Immune metabolism; Combination therapy
Categories
Funding
- Japan Agency for Medical Research and Development [18cm0106302h0003, 18lk1403006h0002] Funding Source: Medline
- Japan Society for the Promotion of Science [17K19593, 19K17673, 16H06149] Funding Source: Medline
- Grants-in-Aid for Scientific Research [19K17673, 16H06149, 17K19593] Funding Source: KAKEN
Ask authors/readers for more resources
Programmed cell death 1 (PD-1) signal receptor blockade has revolutionized the field of cancer therapy. Despite their considerable potential for treating certain cancers, drugs targeting PD-1 still present two main drawbacks: the substantial number of unresponsive patients and/or patients showing recurrences, and side effects associated with the autoimmune response. These drawbacks highlight the need for further investigation of the mechanisms underlying the therapeutic effects, as well as the need to develop novel biomarkers to predict the lack of treatment response and to monitor potential adverse events. Combination therapy is a promising approach to improve the efficacy of PD-1 blockade therapy. Considering the increasing number of patients with cancer worldwide, solving the above issues is central to the field of cancer immunotherapy. In this review, we discuss these issues and clinical perspectives associated with PD-1 blockade cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available